SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout!
LGND 195.35-0.8%Dec 2 3:59 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: george damas who wrote (11564)12/31/1997 11:33:00 AM
From: Henry Niman  Read Replies (3) of 32384
 
george, It looks like LGND is trying to get its story out. In addition to the NBC4 News story in Washington D.C. (at Lombardi), there was a similar show with patients at M.D. Anderson. In this case, the vial with Ligand's name was show. A similar segment was also shown in Louisville, KY, but I don't know if these were KY patients or a re-run of the Lombardi or M.D. Anderson patients.

In any event, the story is the same. Although the drugs don't work on all patients, in some patients the results can be quite dramatic.
The low toxicity profile of Targretin, Panretin, and I assume ALRT1550, should move these retinoids and rexinoids into the fore-front against many cancers, not just the releative rare cancers that are being targeted in the pivotal Phase III trials that are finishing up.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext